Patisiran

Drug Profile

Patisiran

Alternative Names: ALN-TTR02; GENZ-438027; SAR-438037

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Oligonucleotides; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Amyloid polyneuropathy
  • Phase II Amyloidosis

Most Recent Events

  • 16 Nov 2017 Preregistration for Amyloid polyneuropathy in USA (IV)
  • 13 Nov 2017 Patisiran receives accelerated assessment status in Europe for Amyloidosis
  • 02 Nov 2017 Additional efficacy data from the phase III APOLLO trial in Amyloid polyneuropathy released by Alnylam
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top